Analysts Offer Insights on Healthcare Companies: Intersect ENT (NASDAQ: XENT) and Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intersect ENT (NASDAQ: XENT) and Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) with bullish sentiments.

Intersect ENT (NASDAQ: XENT)

In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Buy rating on Intersect ENT (NASDAQ: XENT), with a price target of $46. The company’s shares opened today at $41.10, close to its 52-week high of $42.25.

According to TipRanks.com, Rose is a 5-star analyst with an average return of 11.2% and a 56.9% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Smith & Nephew Snats.

Currently, the analyst consensus on Intersect ENT is Moderate Buy and the average price target is $42, representing a 2.2% upside.

In a report released today, J.P. Morgan also reiterated a Buy rating on the stock with a $48 price target.

Find more picks by Best Performing Analysts >>

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) today. The company’s shares opened today at $111.87.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 32.9% and a 54.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.

Madrigal Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $163.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.